Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxystilbamidine is a synthetic diamidine compound with antifungal, antitrypanosomal, antimalarial, and carcinostatic activities. It acts primarily by binding to DNA and RNA in a non-intercalating manner and inhibiting ribonucleases. In protozoa such as trypanosomes, it binds selectively to kinetoplastic DNA and inhibits cell division. In yeast and other organisms it can bind extranuclear DNA causing mutations. Hydroxystilbamidine also accumulates in lysosomes where it may stabilize lysosomal membranes or increase the number of lysosome-like bodies. Clinically, it was used for the treatment of blastomycosis (a fungal infection) and leishmaniasis but has largely been replaced by amphotericin B due to safety concerns. Additionally, its fluorescent properties have led to its use as a retrograde neuronal tracer under the name Fluoro-Gold[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxystilbamidine.